Arrowhead gets Euro orphan tag for RNAi med candidate

Arrowhead announced that the European Medicines Agency, or EMA, Committee for Orphan Medicinal Products, or COMP, issued a positive opinion on Arrowhead’s application for orphan designation of its RNAi candidate, ARO-AAT, for the treatment of congenital alpha-1 antitrypsin deficiency. ARO-AAT was previously granted orphan drug designation by the FDA in February.

https://bit.ly/2MuiCot